trial

Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia

NCTId NCT03075657
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 120 (actual)
Sponsored by All India Institute of Medical Sciences, Bhubaneswar
Primary completion 2018-06-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
120 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2017-05-01
Primary completion
2018-06-15
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
RisperidoneHaloperidol

Sponsors

All India Institute of Medical Sciences, BhubaneswarLead Sponsor

Investigators

1
Debasish Hota, MD, DMStudy Chair

Sites

1 total
Bhubaneswar, India

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE4
Primary Completion Date
2018-06-15
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Haloperidol
drug
lead_sponsor
All India Institute of Medical Sciences, Bhubaneswar
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Debasish Hota, MD, DM
person